GLP-1 and Kidney Stones: Risk Factors and Safety Considerations

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medications may increase kidney stone risk through mechanisms including dehydration, reduced urine output, and elevated uric acid levels—but clinical evidence shows risk varies significantly based on individual metabolic factors and baseline kidney health. Recent case reports and pharmacovigilance data suggest kidney stone incidence is not universal among GLP-1 users, making personalization essential.

If you're considering compounded semaglutide, tirzepatide, or other GLP-1 therapy, understanding your personal risk factors before starting allows you to work with your provider on preventive hydration strategies and monitoring. PlexusDx helps contextualize this decision through genetic and biomarker insights aligned with evidence-based safety protocols.

How GLP-1 Medications May Affect Kidney Stone Risk

GLP-1 drugs slow gastric emptying and reduce appetite, often leading to lower fluid intake—a primary risk factor for kidney stone formation. Dehydration concentrates urine solutes, promoting crystallization. Additionally, GLP-1 therapy may increase serum uric acid levels through weight loss-related purine metabolism shifts, further elevating nephrolithiasis risk in susceptible individuals.

The mechanism is not direct kidney damage but rather altered hydration and metabolic byproducts. Most kidney stones form from calcium oxalate or uric acid. GLP-1 users who maintain consistent hydration and monitor urine output typically experience lower stone incidence, suggesting prevention is actionable and personalized.

Individual Risk Factors: A Framework for Personalized Assessment

Not all GLP-1 users develop kidney stones. Risk depends on pre-existing kidney function, family history of nephrolithiasis, baseline uric acid levels, diet composition, and hydration habits. Patients with prior kidney stones, gout, or reduced eGFR face higher risk and benefit from baseline kidney biomarker review before therapy initiation.

Risk Factor	Clinical Significance
Prior kidney stone history	Substantially increases recurrence risk; baseline imaging and uric acid assessment recommended
eGFR < 60 mL/min/1.73m²	Reduced kidney clearance; requires provider oversight and possibly alternative GLP-1 dosing
Serum uric acid > 7 mg/dL	May indicate predisposition to uric acid stones; consider baseline and monitoring protocol
Low baseline hydration habits	Dehydration + GLP-1 appetite suppression compounds risk; proactive fluid intake strategy essential
Family history of gout or nephrolithiasis	Genetic predisposition to urate metabolism; may warrant closer monitoring during therapy

Biomarker Context: What to Assess Before Starting GLP-1 Therapy

Before initiating GLP-1 therapy, baseline kidney biomarkers—including serum creatinine, eGFR, uric acid, and 24-hour urine calcium and citrate—provide essential context for individual risk. These measurements help your provider establish a safety baseline and identify whether preventive interventions (like increased hydration or dietary adjustments) are warranted before you start treatment.

The Precision Peptide Genetic Test examines variants in metabolic pathways that influence how your body processes peptides and regulates glucose and lipid metabolism, potentially providing context for baseline uric acid patterns and fluid retention tendencies. This information may help support a more informed conversation with your provider about kidney stone risk factors specific to your genetic predisposition in peptide-related pathways.

Practical Prevention and Provider Guidance for GLP-1 Safety

The primary prevention strategy is aggressive hydration. GLP-1 users should aim for 2.5–3 liters of water daily, increase electrolyte intake, and monitor urine color (pale yellow indicates adequate hydration). Dietary adjustments—including reduced sodium, balanced animal protein, and adequate citrate—further support kidney stone prevention alongside pharmacological therapy.

If you experience flank pain, urinary frequency changes, or cloudy urine while on GLP-1 therapy, contact your healthcare provider immediately. Regular kidney function monitoring (eGFR, uric acid) every 6–12 months during GLP-1 use supports early detection of adverse trends. Your provider can adjust dosing, hydration protocols, or explore compounded GLP-1 alternatives if kidney stone risk emerges.

How PlexusDx Supports a More Personalized Approach

PlexusDx compounded GLP-1 options (semaglutide injection, oral semaglutide, tirzepatide injection, oral tirzepatide) are offered through licensed 503A pharmacies with flexible dosing and formulation adjustments. Biomarker context—including baseline kidney function and uric acid—may help inform whether a lower starting dose, microdose protocol, or alternative formulation better aligns with your kidney stone risk profile and provider recommendations.

The Precision Peptide Genetic Test examines FTO rs9939609, MC4R rs17782313, GLP1R rs6923761, and GIPR rs1800437 variants, which may provide context for metabolic efficiency, appetite regulation, and how your body processes peptide therapies. These predispositions in peptide-related genetic pathways do not predict exact kidney stone risk but may inform baseline metabolic patterns your provider should assess alongside standard kidney biomarkers.

Understanding your genetic predispositions and biomarker profile before initiating compounded GLP-1 therapy can support a more targeted conversation with your provider about hydration strategies, monitoring frequency, and whether your specific risk factors warrant dietary or supplemental interventions to minimize kidney stone risk.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.